Leading pharmacy benefit managers are shifting away from lucrative rebates on biologic drugs and toward lower-cost biosimilar ...

CVS Health Inc (NYSE:CVS) on Tuesday named Brian Newman as executive vice president and chief financial officer designate, ...

CVS Health Corporation’s CVS share price has dipped by 6.47%, which has investors questioning if this is right time to buy.

CVS Health subsidiary CVS Caremark, Cigna division Express Scripts and UnitedHealth Group unit OptumRx collectively hold 70% of the PBM market, according to the American Medical Association.

CVS Health (CVS) is a top S&P 500 performer in 2025, with year-to-date returns exceeding 50%. Moreover, the stock has shirked ...

Brian Newman will guide CVS’ finances at a challenging time for the retail pharmacy and health insurance giant. Still, CVS ...

The CEOs of CVS Health and UnitedHealth Group praised pharmacy benefit managers and promised transparency during investor ...

Tuesday, lawmakers in Arkansas advanced a bill that would essentially eliminate a popular pharmacy chain in the Natural State ...

Arkansas Gov. Sarah Sanders has signed a first-in-the-nation law that prohibits PBMs from operating both retail and ...

Omada Health is joining forces with CVS Health's Caremark as part of the pharmacy benefit manager's weight management program. This marks Omada's second partnership with a major PBM, following its ...

CVS Health is a BUY. Undervalued with growth potential, it outshines competitors despite sector challenges. See more on CVS ...

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $74.12, accompanied by ...